Literature DB >> 12949288

Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus.

Roberta L Keller1, Ronald I Clyman.   

Abstract

OBJECTIVE: Although indomethacin produces ductus arteriosus constriction in extremely premature newborns, a recurrent symptomatic patent ductus arteriosus (PDA) frequently develops after the initial course of indomethacin. Currently, there is little information available to determine the effectiveness of a second course of indomethacin in producing permanent ductus closure. The objective of this study was to determine the rate of permanent ductus closure after a second course of indomethacin for a recurrent, symptomatic PDA and to identify the factors associated with permanent ductus closure.
METHODS: We identified 32 infants (<28 weeks' gestational age) 1) whose ductus was considered to be clinically closed after an initial course of indomethacin and 2) who subsequently developed a symptomatic PDA and received a second course of indomethacin. Clinical variables were evaluated for their association with failure of the second course (defined as surgical ligation after the second course for recurrence of a hemodynamically significant PDA). Data were analyzed by chi(2) analysis, Fisher's exact test, and the Mann-Whitney rank sum test.
RESULTS: After the second course of indomethacin, 56% (18 of 32) of the infants had persistent or recurrent PDA-related symptoms that were considered to be hemodynamically significant. The only significant predictor of failure of the second indomethacin course was the demonstration (by Doppler echocardiogram) of persistent ductus flow within 24 hours of completing the initial indomethacin course. All of the 9 newborns with persistent Doppler ductus flow after the initial indomethacin course failed the second course of indomethacin. In contrast, only 39% (9 of 23) of newborns with absent Doppler flow after the initial indomethacin course failed the second course of indomethacin.
CONCLUSIONS: Newborns who are <28 weeks' gestational age and develop a recurrent, symptomatic PDA after completion of an initial indomethacin course rarely respond to multiple courses of indomethacin if there was persistent Doppler evidence of ductus flow after completion of the initial course. Additional indomethacin treatment is unlikely to produce permanent ductus closure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12949288     DOI: 10.1542/peds.112.3.583

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  13 in total

1.  Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment.

Authors:  Nami Jhaveri; Anita Moon-Grady; Ronald I Clyman
Journal:  J Pediatr       Date:  2010-09       Impact factor: 4.406

2.  Intravenous paracetamol for PDA closure in the preterm: a single-center experience.

Authors:  Enrico Valerio; Marta Rossella Valente; Sabrina Salvadori; Anna Chiara Frigo; Eugenio Baraldi; Paola Lago
Journal:  Eur J Pediatr       Date:  2016-05-05       Impact factor: 3.183

3.  Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach.

Authors:  Andra Malikiwi; Charlene Roufaeil; Kenneth Tan; Arvind Sehgal
Journal:  Eur J Pediatr       Date:  2014-10-26       Impact factor: 3.183

4.  Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.

Authors:  Nansi S Boghossian; Barbara T Do; Edward F Bell; John M Dagle; Jane E Brumbaugh; Barbara J Stoll; Betty R Vohr; Abhik Das; Seetha Shankaran; Pablo J Sanchez; Myra H Wyckoff; M Bethany Ball
Journal:  Early Hum Dev       Date:  2017-07-08       Impact factor: 2.079

Review 5.  Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period.

Authors:  Jeff Reese; Alex Veldman; Lisa Shah; Megan Vucovich; Robert B Cotton
Journal:  Semin Perinatol       Date:  2010-06       Impact factor: 3.300

6.  Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome.

Authors:  Juliette C Madan; Douglas Kendrick; James I Hagadorn; Ivan D Frantz
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

7.  Indomethacin use for the management of patent ductus arteriosus in preterms: a web-based survey of practice attitudes among neonatal fellowship program directors in the United States.

Authors:  S B Amin; C Handley; O Carter-Pokras
Journal:  Pediatr Cardiol       Date:  2007-04-24       Impact factor: 1.655

8.  Multiple courses of indomethacin and neonatal outcomes in premature infants.

Authors:  Madhavi Sangem; Sumita Asthana; Sanjiv Amin
Journal:  Pediatr Cardiol       Date:  2007-12-18       Impact factor: 1.655

9.  Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus.

Authors:  N Margreth van der Lugt; Enrico Lopriore; Regina Bökenkamp; Vivianne E H J Smits-Wintjens; Sylke J Steggerda; Frans J Walther
Journal:  Eur J Pediatr       Date:  2012-08-05       Impact factor: 3.183

10.  Patent ductus arteriosus in premature neonates.

Authors:  Olachi J Mezu-Ndubuisi; Ghanshyam Agarwal; Aarti Raghavan; Jennifer T Pham; Kirsten H Ohler; Akhil Maheshwari
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.